A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Status: Recruiting
Location: See all (40) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016 onwards.
• Patients who died are allowed to be included on the study.
• Able and willing to provide written informed consent if they are alive.
• Age ≥ 18 years.
• Availability to medical records access and all data related to the disease management.
Locations
Other Locations
Spain
Complejo Hospitalario Universitario A Coruña
RECRUITING
A Coruña
Complejo Hospitalario Universitario de Albacete
RECRUITING
Albacete
Hospital Universitario Fundación Alcorcón
RECRUITING
Alcorcón
Hospital San Juan de Alicante
RECRUITING
Alicante
Hospital Nuestra Señora de Sonsoles
RECRUITING
Ávila
Hospital Clinic de Barcelona
WITHDRAWN
Barcelona
Hospital del Mar
RECRUITING
Barcelona
Hospital Moisés Broggi_institut Catalá D´Oncologia
RECRUITING
Barcelona
Hospital Santa Creu i Sant Pau
RECRUITING
Barcelona
Hospital Universitario Germans Trias i Pujol
RECRUITING
Barcelona
ICO L´Hospitalet
RECRUITING
Barcelona
Hospital Universitario de Basurto
RECRUITING
Bilbao
Hospital Universitario Reina Sofía
RECRUITING
Córdoba
Hospital General de Elche
RECRUITING
Elche
Hospital Universitario de Fuenlabrada
RECRUITING
Fuenlabrada
Hospital Dr. Negrín
RECRUITING
Las Palmas De Gran Canaria
Hospital Universitario Severo Ochoa
RECRUITING
Leganés
Hospital de León
RECRUITING
León
Hospital Lucus Augusti
RECRUITING
Lugo
Hospital General Universitario Gregorio Marañón
RECRUITING
Madrid
Hospital Universitario La Princesa
RECRUITING
Madrid
Hospital Universitario de Málaga
RECRUITING
Málaga
Althaia-Xarxa Assistencial de Manresa
RECRUITING
Manresa
Hospital Clínico Universitario Virgen de la Arrixaca
RECRUITING
Murcia
Hospital Son Llatzer
RECRUITING
Palma De Mallorca
Complejo Hospitalario de Navarra
RECRUITING
Pamplona
Hospital de Sagunto
RECRUITING
Sagunto
Hospital Clínico Universitario de Salamanca
RECRUITING
Salamanca
Hospital Universitario Donostia
RECRUITING
San Sebastián
Hospital Infanta Sofía
RECRUITING
San Sebastián De Los Reyes
Hospital Universitario de Canarias
RECRUITING
Santa Cruz De Tenerife
Hospital Universitario Virgen del Rocío
RECRUITING
Seville
Consorci Sanitari de Terrassa
RECRUITING
Terrassa
Hospital Virgen de la Salud
RECRUITING
Toledo
Hosital General de Valencia
RECRUITING
Valencia
Hospital Clínico Universitario de Valencia
RECRUITING
Valencia
Hospital Universitario Dr. Peset
RECRUITING
Valencia
IVO-Instituto Valenciano de Oncología
RECRUITING
Valencia
Hospital Clínico Lozano Blesa
RECRUITING
Zaragoza
Hospital Miguel Servet
RECRUITING
Zaragoza
Contact Information
Primary
MS Study Project Manager
inicio_ensayos@geicam.org
+34 916892870
Backup
Start-Up Unit Manager
inicio_ensayos@geicam.org
+34 916892870
Time Frame
Start Date: 2016-08
Estimated Completion Date: 2026-06
Participants
Target number of participants: 1867
Treatments
Luminal A-like subtype
Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (\< 14%).
Luminal B-like (HER2 negative) subtype:
Patients that express ER and are either PgR- or low (\< 20%) and/or Ki67 'high' (≥ 14%).
Luminal B-like (HER2 positive) subtype:
Patients that express ER and HER2 irrespective of PgR or Ki67 status.
HER2-enriched subtype
Patients that express HER2 and don't express ER or PgR.
Triple Negative (TN) subtype
Patients who are negative for the expression of ER, PgR and HER2.
Related Therapeutic Areas
Sponsors
Collaborators: Hoffmann-La Roche, Pfizer, Celgene, AstraZeneca, Novartis
Leads: Spanish Breast Cancer Research Group